Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

10/11/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ASRT alert in real time by email

LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Brendan O'Grady, Chief Executive Officer, will participate in a fireside chat discussion as part of the Maxim Group 2024 Healthcare Virtual Summit. The fireside chat with Mr. O'Grady, hosted by Maxim Group research analyst Naz Rahman, will occur Tuesday, October 15, 2024 at 1:00 pm Eastern Time.

Investors can register to listen to the event via https://m-vest.com/events/healthcare-10152024.

About Assertio

Assertio is a commercial pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit www.assertiotx.com.

Investor Contact

Matt Kreps, Managing Director

Darrow Associates

M: 214-597-8200

[email protected]

Get the next $ASRT alert in real time by email

Date	Price Target	Rating	Analyst
7/26/2024	$3.00	Buy	Maxim Group
7/3/2024	$4.00	Buy	H.C. Wainwright
11/7/2022	$7.00	Buy	Lake Street

Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024

Chat with this insight

Recent Analyst Ratings for $ASRT

$ASRT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Maxim Group initiated coverage on Assertio Therapeutics with a new price target

H.C. Wainwright initiated coverage on Assertio Therapeutics with a new price target

Lake Street initiated coverage on Assertio Therapeutics with a new price target

$ASRT Financials

Live finance-specific insights

Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024

Assertio Reports Second Quarter 2024 Financial Results

Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024

$ASRT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP, General Counsel Schlessinger Sam converted options into 19,404 shares and covered exercise/tax liability with 8,595 shares, increasing direct ownership by 9% to 132,864 units (SEC Form 4)

Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

Mason Heather L bought $24,250 worth of shares (25,000 units at $0.97), increasing direct ownership by 13% to 212,650 units (SEC Form 4)

$ASRT Press Releases

Fastest customizable press release news feed in the world

Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024